The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
Open accessAbstract
Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease with a 5-year survival rate of 4%. A key hallmark of PDAC is extensive stromal involvement, which makes capturing precise tumor-specific molecular information difficult. Here we have overcome this problem by applying blind source separation to a diverse collection of PDAC gene expression microarray data, including data from primary tumor, metastatic and normal samples. By digitally separating tumor, stromal and normal gene expression, we have identified and validated two tumor subtypes, including a 'basal-like' subtype that has worse outcome and is molecularly similar to basal tumors in bladder and breast cancers. Furthermore, we define 'normal' and 'activated' stromal subtypes, which are independently prognostic. Our results provide new insights into the molecular composition of PDAC, which may be used to tailor therapies or provide decision support in a clinical setting where the choice and timing of therapies are critical.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moffit and colleagues devised a “virtual dissection strategy” to computationally subtract the transcriptional background imposed by stromal and immune cells from bulk-RNA sequencing signatures131. Using this approach, they identified two subtypes of PDAC tumors, termed “classical” and “basal-like”, in addition to two stromal subtypes termed “normal stroma” and “activated stroma”.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [131]
In the citing paper
“The dichotomous Moffitt classification schema of “basal-like” and “classical” subtypes was initially established using bulk RNA sequencing strategies applied to human tumor samples (Moffitt 2015)36.”
From Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution (2022) · cites this paper as Moffitt 2015
In the citing paper
“The dichotomous Moffitt classification schema of “basal-like” and “classical” subtypes was initially established using bulk RNA sequencing strategies applied to human tumor samples (Moffitt 2015)36.”
From Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution (2022) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Gene Ontology: tool for the unification of biology
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000) · Nature Genetics · doi:10.1038/75556 · Cited by 43,206
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668
Trapnell, C., Roberts, A., Goff, L. A., Pertea, G. M., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,145
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
Self-citationSignatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
The Reactome pathway Knowledgebase
Fabregat, A., Sidiropoulos, K., Garapati, P., Gillespie, M., Hausmann, K., Haw, R., Jassal, B., Jupe, S., Korninger, F., McKay, S., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1351 · Cited by 5,605
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S. C. Y., Voduc, D. K., Vickery, T. L., Davies, S. R., Fauron, C. M. ‐., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,818
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,002
Abd-El-Halim, Y. M., Kaoutari, A. E., Silvy, F., Rubis, M., Bigonnet, M., Roques, J., Cros, J. F., Nicolle, R., Iovanna, J., Dusetti, N., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103541 · Cited by 44
Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer
Veghini, L., Pasini, D., Fang, R., Delfino, P., Filippini, D., Neander, C., Vicentini, C., Fiorini, E., Lupo, F., D’Agosto, S. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54975-8 · Cited by 46
Alonso, S., Hernandez, D., Chang, Y., Gocke, C., McCray, M. E., Varadhan, R., Matsui, W. H., Jones, R. J., & Ghiaur, G. (2016) · Journal of Clinical Investigation · doi:10.1172/jci88152 · Cited by 43
Tesfaye, A. A., Kamgar, M., Azmi, A. S., & Philip, P. A. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1417844 · Cited by 43
Dreyer, S. B., Jamieson, N. B., Evers, L., Duthie, F. R., Cooke, S., Marshall, J., Beraldi, D., Knight, S. R., Upstill‐Goddard, R., Dickson, E. J., et al. (2019) · Chinese Clinical Oncology · doi:10.21037/cco.2019.04.06 · Cited by 43
Mii, S., Enomoto, A., Shiraki, Y., Taki, T., Murakumo, Y., & Takahashi, M. (2019) · Pathology International · doi:10.1111/pin.12798 · Cited by 43
Dissecting the Oncogenic Roles of Keratin 17 in the Hallmarks of Cancer
Baraks, G., Tseng, R., Pan, C., Kasliwal, S., Leiton, C. V., Shroyer, K. R., & Escobar-Hoyos, L. F. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2522 · Cited by 42
Assessment of spatial transcriptomics for oncology discovery
Lyubetskaya, A., Rabe, B. A., Fisher, A., Lewin, A. C., Neuhaus, I., Brett, C., Brett, T., Pereira, E. R., Golhar, R., Kebede, S., et al. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100340 · Cited by 42
Sun, N., Kabir, M., Lee, Y., Xie, L., Hu, X., Velez, J., Chen, X., Kanıskan, H. Ü., & Jin, J. J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01505 · Cited by 43
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Singh, H., Xiu, J., Kapner, K. S., Yuan, C., Narayan, R. R., Oberley, M. J., Farrell, A. P., Surana, R., Huffman, B. M., Perez, K. J., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1164 · Cited by 47
Pancreatic Cancer Diagnosis and Management: Has the Time Come to Prick the Bubble?
Moutinho-Ribeiro, P., Macedo, G., & Melo, S. A. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00779 · Cited by 43
Precision medicine in pancreatic cancer: treating every patient as an exception
Herbst, B. T., & Zheng, L. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30175-x · Cited by 42
Zhu, Y., Yu, F., Tan, Y., Hong, Y. K., Meng, T., Liu, Y., Dai, S., Qiu, G., Yuan, H., & Hu, F. (2019) · Theranostics · doi:10.7150/thno.36334 · Cited by 42
Alkallas, R., Lajoie, M., Moldoveanu, D., Hoang, K. V., Lefrançois, P., Lingrand, M., Ahanfeshar-Adams, M., Watters, K. A., Spatz, A., Zippin, J. H., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0077-8 · Cited by 43
Yu, Y., Yang, G., Huang, H., Fu, Z., Cao, Z., Zheng, L., You, L., & Zhang, T. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01787-5 · Cited by 42
Gupta, N., & Yelamanchi, R. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i23.3158 · Cited by 47
Pihlak, R., Weaver, J. M. J., Valle, J. W., & McNamara, M. G. (2018) · Cancers · doi:10.3390/cancers10010017 · Cited by 42
Identifying Molecular Biomarkers for Diseases With Machine Learning Based on Integrative Omics
Shi, K., Lin, W. J., & Zhao, X. (2020) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2020.2986387 · Cited by 43
Topham, J. T., Tsang, E. S., Karasinska, J. M., Metcalfe, A. L., Ali, H., Kalloger, S. E., Csizmók, V., Williamson, L., Titmuss, E., Nielsen, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33718-7 · Cited by 41
Progress on diagnostic and prognostic markers of pancreatic cancer
YANG, H., Li, W., Ren, L., Yang, Y., Zhang, Y., Ge, B., Li, S., Zheng, X., Liu, J., Zhang, S., et al. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.028905 · Cited by 43
Storrs, E. P., Chati, P., Usmani, A., Sloan, I. H., Krasnick, B. A., Babbra, R. K., Harris, P. K. W., Sachs, C. M., Qaium, F., Chatterjee, D., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00455-z · Cited by 48
Self-citationPark, J. K., Jeong, H., Kim, H. M., Choi, J. H., Lee, E. M., Kim, S., Jang, J., Choi, D. W.-Y., Lee, S., Kim, K. M., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02003-0 · Cited by 43
Self-citationPerioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini, M., Salem, R. R., Robert, M. E., Czerniak, S., Bláha, O., Zelterman, D. A., Rajaei, M., Townsend, J. P., Cai, G., Chowdhury, S., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.1575 · Cited by 46
Link, J. M., Eng, J. R., Pelz, C., Hawthorne, K., Worth, P. J., Sivagnanam, S., Keith, D., Owen, S., Langer, E. M., Grossblatt-Wait, A., et al. (2025) · Nature Cancer · doi:10.1038/s43018-024-00881-3 · Cited by 44
Knox, J. J., O'Kane, G. M., King, D. A., Laheru, D. A., Habowski, A. N., Yu, K. H., Perez, K. J., Aguirre, A. J., Coyne, Z. L., Harvey, H. M., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00436 · Cited by 41
Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling
Humphrey, E. S., Su, S., Nagrial, A. M., Hochgräfe, F., Pajic, M., Lehrbach, G. M., Parton, R. G., Yap, A. S., Horvath, L. G., Chang, D. K.-F., et al. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.058313 · Cited by 40
Stromal SPOCK 1 supports invasive pancreatic cancer growth
Veenstra, V. L., Damhofer, H., Waasdorp, C., Steins, A., Kocher, H. M., Medema, J. P., van Laarhoven, H. W. M., & Bijlsma, M. F. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12073 · Cited by 41
Ductal vs. acinar? Recent insights into identifying cell lineage of pancreatic ductal adenocarcinoma
Xu, Y., Liu, J., Nipper, M. H., & Wang, P. (2019) · Annals of Pancreatic Cancer · doi:10.21037/apc.2019.06.03 · Cited by 39
Mundry, C. S., Eberle, K. C., Singh, P. K., Hollingsworth, M. A., & Mehla, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188387 · Cited by 41
Self-citationRepurposing metformin for the treatment of gastrointestinal cancer
Júnior, A. D. D. C., Bragagnoli, A. S. C., Costa, F. O., & Carvalheira, J. B. C. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i17.1883 · Cited by 42
Striefler, J. K., Riess, H. B., Lohneis, P., Bischoff, S., Kurreck, A., Modest, D. P., Bahra, M., Oettle, H., Sinn, M., Bläker, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670396 · Cited by 41
Li, C., Zeng, X., Yu, H., Gu, Y., & Zhang, W. (2018) · World Journal of Surgical Oncology · doi:10.1186/s12957-018-1519-y · Cited by 40
A p300/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models
Zhong, Z., Harmston, N., Wood, K. C., Madan, B., & Virshup, D. M. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156305 · Cited by 39
Role of microenvironmental periostin in pancreatic cancer progression
Liu, Y., Li, F., Gao, F., Xing, L., Qin, P., Liang, X., Zhang, J., Qiao, X.-H., Lin, L., Zhao, Q., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11533 · Cited by 39
Sandberg, T. P., Oosting, J., van Pelt, G. W., Mesker, W. E., Tollenaar, R. A. �. �., & Morreau, H. (2018) · Oncotarget · doi:10.18632/oncotarget.25845 · Cited by 39
High‐grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF‐1
Steins, A., van Mackelenbergh, M. G., van der Zalm, A. P., Klaassen, R., Serrels, B., Goris, S. G., Kocher, H. M., Waasdorp, C., de Jong, J. H., Tekin, C., et al. (2020) · EMBO Reports · doi:10.15252/embr.201948780 · Cited by 38
Lipner, M. B., Peng, X. L., Jin, C., Xu, Y., Gao, Y., East, M. P., Rashid, N. U., Moffitt, R. A., Hererra, S. G., Morrison, A. B., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.129905 · Cited by 39
Self-citationPancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis
Pompella, L., Tirino, G., Pappalardo, A., Caterino, M., Ventriglia, A., Nacca, V., Orditura, M., Ciardiello, F., & Vita, F. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082814 · Cited by 40
Thompson, E. D., Roberts, N. J., Wood, L. D., Eshleman, J. R., Goggins, M., Kern, S. E., Klein, A. P., & Hruban, R. H. (2020) · Modern Pathology · doi:10.1038/s41379-020-0629-6 · Cited by 41
Berry, W., Algar, E. M., Kumar, B., Desmond, C., Swan, M. P., Jenkins, B. J., & Croagh, D. G. (2017) · International Journal of Cancer · doi:10.1002/ijc.30648 · Cited by 40
Andersen, H. B., Ialchina, R., Pedersen, S. F., & Czaplińska, D. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-10004-4 · Cited by 40
Rodríguez, E., Boelaars, K., Brown, K., Madunić, K., van Ee, T., Dijk, F., Verheij, J., Li, R. J. E., Schetters, S. T. T., Meijer, L. L., et al. (2022) · Communications Biology · doi:10.1038/s42003-021-02934-0 · Cited by 38
Modeling Pancreatic Cancer with Patient-Derived Organoids Integrating Cancer-Associated Fibroblasts
Go, Y.-H., Choi, W. H., Bae, W. J., Jung, S., Cho, C., Lee, S. A., Park, J. S., Ahn, J. M., Kim, S. W., Lee, K. J., et al. (2022) · Cancers · doi:10.3390/cancers14092077 · Cited by 39
de Andrés, M. P., Jackson, R., Felipe‐Abrio, I., Zagorac, S., Pilarsky, C. P., Schlitter, A. M., de Villarreal, J. M., Jang, G. H., Costello, E., Gallinger, S., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-325803 · Cited by 36
Ohara, Y., Tang, W., Liu, H., Yang, S., Dorsey, T. H., Cawley, H., Moreno, P., Chari, R., Guest, M., Azizian, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113434 · Cited by 41
Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future
Barhli, A., Cros, J. F., Bartholin, L., & Neuzillet, C. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.08.009 · Cited by 40
Odyssey of trefoil factors in cancer: Diagnostic and therapeutic implications
Jahan, R., Shah, A., Kisling, S. G., Macha, M. A., Thayer, S. P., Batra, S. K., & Kaur, S. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188362 · Cited by 39
Molecular and Metabolic Subtypes Correspondence for Pancreatic Ductal Adenocarcinoma Classification
Espiau-Romera, P., Courtois, S., Parejo-Alonso, B., & Sancho, P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9124128 · Cited by 43
Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical Impact
Gutiérrez, M. L., Muñoz‐Bellvís, L., & Órfão, A. (2021) · Cancers · doi:10.3390/cancers13174451 · Cited by 41
NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer
Doffo, J., Bamopoulos, S. A., Köse, H., Orben, F., Zang, C., Pons, M., den Dekker, A. T., Brouwer, R. W. W., Baluapuri, A., Habringer, S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2105691119 · Cited by 36
Murphy, K. J., Chambers, C. R., Herrmann, D., Timpson, P., & Pereira, B. (2021) · Cancers · doi:10.3390/cancers13143481 · Cited by 37
Tanaka, H. Y., Nakazawa, T., Enomoto, A., Masamune, A., & Kano, M. R. (2023) · Cancers · doi:10.3390/cancers15030724 · Cited by 42
PUREE: accurate pan-cancer tumor purity estimation from gene expression data
Revkov, E., Kulshrestha, T., Sung, K. W.-K., & Skanderup, A. J. (2023) · Communications Biology · doi:10.1038/s42003-023-04764-8 · Cited by 38
Brown, B. A., Myers, P. J., Adair, S. J., Pitarresi, J. R., Sah‐Teli, S. K., Campbell, L. A., Hart, W. S., Barbeau, M. C., Leong, K. M., Seyler, N. M., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-22-2945 · Cited by 40
Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial
Knox, J. J., Jang, G. H., Grant, R. C., Zhang, A. X. W., Ma, L. X., Elimova, E. C., Jang, R., Moore, M. J., Biagi, J. J., Tehfe, M. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60808-z · Cited by 39
The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma
Sandhu, V., Wedge, D. C., Lothe, I. M. B., Labori, K. J., Dentro, S. C., Buanes, T. A., Skrede, M. L., Dalsgaard, A. M., Munthe, E., Myklebost, O., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0658 · Cited by 37
Clinical study of genomic drivers in pancreatic ductal adenocarcinoma
Barrett, M. T., Deiotte, R., Lenkiewicz, E., Malasi, S., Holley, T., Evers, L., Posner, R. G., Jones, T., Han, H., Sausen, M., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.209 · Cited by 38
Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma
Schofield, H. K., Zeller, J., Espinoza, C. E., Halbrook, C. J., Vecchio, A. D., Magnuson, B., Fabo, T., Daylan, A. E. C., Kovalenko, I., Lee, H., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.97422 · Cited by 38
Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance
Chiou, S., Dorsch, M., Kusch, E., Naranjo, S., Kozak, M. M., Koong, A. C., Winslow, M. M., & Grüner, B. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-32159-x · Cited by 37
Panzeri, V., Manni, I., Capone, A., Naro, C., Sacconi, A., Agostino, S. D., de Latouliere, L., Montori, A., Pilozzi, E., Piaggio, G., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12847 · Cited by 37
Dhara, S., Chhangawala, S., Chintalapudi, H., Aşkan, G., Aveson, V. G., Massa, A. L., Zhang, L., Torres, D., Makohon-Moore, A. P., Lecomte, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23237-2 · Cited by 37
Self-citationN6-Methylandenosine-Related lncRNAs Predict Prognosis and Immunotherapy Response in Bladder Cancer
Zhang, Y., Zhu, B., He, M., Cai, Y., Ying, X., Jiang, C., Ji, W., & Zeng, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.710767 · Cited by 36
Chakrabarti, S., Kamgar, M., & Mahipal, A. (2022) · Cancers · doi:10.3390/cancers14112588 · Cited by 36
Cancer-Associated Fibroblast Diversity Shapes Tumor Metabolism in Pancreatic Cancer
Peiffer, R., Boumahd, Y., Gullo, C., Crake, R., Letellier, E., Bellahcène, A., & Peulen, O. (2022) · Cancers · doi:10.3390/cancers15010061 · Cited by 38
Decoding the basis of histological variation in human cancer
Fujii, M., Sekine, S., & Sato, T. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00648-5 · Cited by 35
Nakazawa, Y., Miyano, M., Tsukamoto, S., Kogai, H., Yamamoto, A., Iso, K., Inoue, S., Yamane, Y., Yabe, Y., Umihara, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46167-1 · Cited by 37
Tang, R., Zhang, Z., Liu, X., Liao, Y., Chen, Y., Xiao, M., Li, Y., Zhou, C., Tan, Z., Zhang, C., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.03.019 · Cited by 36
Pitarresi, J. R., Liu, X., Sharma, S. M., Cuitiño, M. C., Kladney, R. D., Mace, T. A., Donohue, S., Nayak, S. G., Qu, C., Lee, J., et al. (2016) · Neoplasia · doi:10.1016/j.neo.2016.07.006 · Cited by 36
Mao, S., Zhang, Q., Liu, W., Huang, Q., Khan, M., Zhang, W., Lin, C., Uchiyama, K., & Lin, J. (2018) · Chemical Science · doi:10.1039/c8sc05104f · Cited by 36
Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In?
Tsang, E. S., Topham, J. T., Karasinska, J. M., Lee, M. K. C., Williamson, L., Mendis, S. R., Denroche, R. E., Jang, G. H., Kalloger, S. E., Moore, R. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1042 · Cited by 37
The Tumor Microenvironment of Pancreatic Cancer
Karamitopoulou, E. (2020) · Cancers · doi:10.3390/cancers12103076 · Cited by 37
Creeden, J. F., Alganem, K., Imami, A. S., Brunicardi, F. C., Liu, S., Shukla, R., Tomar, T., Naji, F., & McCullumsmith, R. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228679 · Cited by 36
Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress
Barcellini, A., Peloso, A., Pugliese, L., Vitolo, V., & Cobianchi, L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s220971 · Cited by 36
Cho, E. J., Kim, M., Jo, D., Kim, J., Oh, J., Chung, H. C., Lee, S.-H., Kim, D., Chun, S., Kim, J., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02034-1 · Cited by 36
Cell Lineage Infidelity in PDAC Progression and Therapy Resistance
Malinova, A., Veghini, L., Real, F. X., & Corbo, V. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.795251 · Cited by 39
Achreja, A., Yu, T., Mittal, A., Choppara, S., Animasahun, O. H., Nenwani, M., Wuchu, F., Meurs, N., Mohan, A., Jeon, J. H., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00636-3 · Cited by 33
Pancreatic cancer: disease dynamics, tumor biology and the role of the microenvironment
Ansari, D., Frieß, H., Bauden, M. P., Samnegård, J., & Andersson, R. E. (2018) · Oncotarget · doi:10.18632/oncotarget.24019 · Cited by 35
Precision medicine in pancreatic cancer — fact or fiction?
Seufferlein, T., & Mayerle, J. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.215 · Cited by 35
Minini, M., & Fouassier, L. (2023) · Current Oncology · doi:10.3390/curroncol30040319 · Cited by 38
Swietlik, J. J., Bärthel, S., Falcomatà, C., Fink, D., Sinha, A., Cheng, J., Ebner, S., Landgraf, P., Dieterich, D. C., Daub, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38171-8 · Cited by 38
George, B., Kudryashova, O. M., Kravets, A. D., Thalji, S. Z., Malarkannan, S., Kurzrock, R., Chernyavskaya, E. F., Gusakova, M., Kravchenko, D., Tychinin, D. I., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.028 · Cited by 35
Li, Y., Tang, S., Wang, H., Zhu, H., Lu, Y., Zhang, Y., Guo, S., He, J., Li, Y., Zhang, Y., et al. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.07.008 · Cited by 45
Haro, M., & Oršulić, S. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00098 · Cited by 35
XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma
Birnbaum, D. J., Finetti, P., Birnbaum, D., Mamessier, É., & Bertucci, F. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050596 · Cited by 35
Felix, T. F., Lapa, R. M. L., de Carvalho, M., Bertoni, N., Tokár, T., de Oliveira, R. A., Rodrigues, M. A. M., Hasimoto, C. N., de Oliveira, W. K., Pelafsky, L., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217421 · Cited by 36
Fraunhoffer, N. A., Abuelafia, A. M., Bigonnet, M., Gayet, O., Roques, J., Telle, E., Santofimia‐Castaño, P., Borrello, M. T., Chuluyán, E., Dusetti, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1232 · Cited by 35
Recent advances in precision medicine for pancreatic ductal adenocarcinoma
Hayashi, H., Higashi, T., Miyata, T., Yamashita, Y., & Baba, H. (2021) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12436 · Cited by 36
Recent advances in artificial intelligence for pancreatic ductal adenocarcinoma
Hayashi, H., Uemura, N., Matsumura, K., Liu, Z., Sato, H. R., Shiraishi, Y., Yamashita, Y., & Baba, H. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i43.7480 · Cited by 40
Perera, S., Jang, G. H., Wang, Y., Kelly, D., Allen, M. J., Zhang, A. X. W., Denroche, R. E., Dodd, A., Ramotar, S., Hutchinson, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2576 · Cited by 35
Kang, Y., Deng, J., Ling, J., Li, X., Chiang, Y., Koay, E. J., Wang, H., Burks, J. K., Chiao, P. J., Hurd, M. W., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci151604 · Cited by 34
A mucus production programme promotes classical pancreatic ductal adenocarcinoma
Tonelli, C., Yordanov, G. N., Hao, Y., Deschênes, A., Hinds, J., Belleau, P., Klingbeil, O., Brosnan, E., Doshi, A., Park, Y., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-329839 · Cited by 34
Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures
Schäfer, T. E., Knol, L. I., Haas, F. V., Hartley, A., Pernickel, S. C. S., Jády, A., Finkbeiner, M. S. C., Achberger, J., Arelaki, S., Modic, Ž., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105219 · Cited by 38
Lan, W., Bian, B., Xia, Y., Dou, S., Gayet, O., Bigonnet, M., Santofimia‐Castaño, P., Cong, M., Peng, L., Dusetti, N., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26613-z · Cited by 34
Hiroshima, Y., Kasajima, R., Kimura, Y., Komura, D., Ishikawa, S., Ichikawa, Y., Bouvet, M., Yamamoto, N., Oshima, T., Morinaga, S., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.031 · Cited by 34
B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma
Minici, C., Rigamonti, E., Lanzillotta, M., Monno, A., Rovati, L., Maehara, T., Kaneko, N., Deshpande, V., Protti, M. P., Monte, L. B. D., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1794359 · Cited by 34
Comparative assessment and novel strategy on methods for imputing proteomics data
Shen, M., Chang, Y.-T., Wu, C.-T., Parker, S. J., Saylor, G., Wang, Y., Yu, G., Eyk, J. E. V., Clarke, R. C., Herrington, D. M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-04938-0 · Cited by 40
Pancreatic cancer – the past, the present, and the future
Andersson, R. E., Haglund, C., Seppänen, H. E., & Ansari, D. (2022) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2022.2067786 · Cited by 36
Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer
Santis, M. C. D., Gozzelino, L., Margaria, J. P., Costamagna, A., Ratto, E., Gulluni, F., Gregorio, E. D., Mina, E., Lorito, N., Bacci, M., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-325117 · Cited by 34
Moving the Needle on Precision Medicine in Pancreatic Cancer
O'Kane, G. M., & Lowery, M. A. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02514 · Cited by 34
Detection of Sources in Non-Negative Blind Source Separation by Minimum Description Length Criterion
Lin, C.-H., Chi, C., Chen, L., Miller, D. J., & Wang, Y. (2017) · IEEE Transactions on Neural Networks and Learning Systems · doi:10.1109/tnnls.2017.2749279 · Cited by 34
Metadata
- Authors
- Moffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G. H., Hoadley, K. A., Rashid, N. U., Williams, L. A., Eaton, S. C., Chung, A. H., Smyla, J. K., Anderson, J. M., Kim, H. J., Bentrem, D. J., Talamonti, M. S., Iacobuzio-Donahue, C. A., Hollingsworth, M. A., & Yeh, J. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- University of Nebraska–Lincoln (US)
- Northwestern University (US)
- Corresponding author
- Yeh, Jen Jen
- ORCID
- Venue
- Nature Genetics
- Published
- 2015-09-07
- Volume
- 47
- Issue
- 10
- Pages
- 1168-1178
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- PMC
- PMC4912058
- OpenAlex
- W1497915798
- Cited by
- 2,194
- References
- 63
- Citations by year
- 2026: 227 · 2025: 237 · 2024: 236 · 2023: 252 · 2022: 256 · 2021: 298 · 2020: 223 · 2019: 168 · 2018: 124 · 2017: 96 · 2016: 65 · 2015: 9
- FWCI
- 42.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (T32CA009156, R01CA140424, P30CA060553)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30-DK034897, P30DK034987)
- National Institute of Environmental Health Sciences (P30ES010126)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- pancreatic ductal adenocarcinoma, tumor stroma, tumor subtypes, gene expression signatures, blind source separation, basal-like subtype, prognostic subtypes, metastatic pancreatic cancer, molecular classification
- MeSH terms
- Adenocarcinoma, Animals, Female, Humans, Male, Pancreatic Neoplasms, Gene Expression, Stromal Cells, Genetic Heterogeneity, Carcinoma, Pancreatic Ductal, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
